Acceso abierto

Surgical resection of synchronous liver metastases in gastric cancer patients. A propensity score-matched study


Cite

Figure 1

Cumulative survivals of patients with liver metastases without resection, with liver resection and in the control group respectively.
Cumulative survivals of patients with liver metastases without resection, with liver resection and in the control group respectively.

Figure 2

Survival of subgroups. Overall survival according age (A), tumour differentiation (B), serum CA-19 level (C), N stage of TNM (D) and serum haemoglobin (E).
Survival of subgroups. Overall survival according age (A), tumour differentiation (B), serum CA-19 level (C), N stage of TNM (D) and serum haemoglobin (E).

Morbidity and mortality of additional resections in in the control group of patients without liver metastases and stage III and IV resectable gastric cancer (CG)

N (%)Morbidity (%)Mortality (%)
Gastrectomy
        Subtotal4(19)0(0)1(25)
        Total12(57.1)2(16.6)1(25)
        Total with distal esophagectomy4(19)1(25)0(0)
        Stump resection1(4.8)0(0)0(0)
Additional resection
        No additional resection         Local peritonectomy         Left splenopancreatectomy and         segmental colon resection11(52.4) 8(4.8) 1(4.8)1(9.1) 1(12.5) 0(0)2(18.2) 0(0) 0(0)
        Left left adrenal splenopancreatectomy resection and1(4.8)1(100)0(0)

Characteristics of liver resections in the group of patients with synchronous liver metastases and gastric resection with curative intent (LMR)

n(%)
Segment involvement
        I0(0)
        II2(8.6)
        II/III3(13)
        III9(39.1)
        IV2(8.6)
        V2(8.6)
        VI0(0)
        VII3(13)
        VIII2(8.6)
Liver resection
        Metastasectomia of 1 metastasis12(57.1)
        Metastasectomia of >1 metastasis3(14.3)
        Segmental resection3(14.3)
        Hepatectomy1(4.8)
        Radio frequency ablation2(9.5)
Dindo-Claviene morbidity
        018(85.7)
        II1(4.8)
        IIIa0(0)
        IIIb1(4.8)
        V1(4.8)
Number of metastases
        1 metastasis19(90.5)
        2–3 metastasis2(9.5)
        > 3 metastasis0(0)

Patients’, tumour and operations characteristics of the included patients

PSM groups
All patientsLM0LMRCGp
Age [years ± SD]64.43 ± 9.964.9 ± 6.965.5 ± 1062.7 ± 12.5NS
Gender [n(%)]
        Male50(79.4)17(81)16(76.2)17(81)NS
        Female13(20.6)4(19)5(23.8)4(19)
CA 19-9 [ng(IQR)]13(64.7)20(32)7(62)5.5(351.7)NS
CEA [ng(IQR)]4(6.5)3.5(26.7)4(6)3(17.25)NS
Hb [g/l(IQR)]112.5(28.25)117.5(25)105(41)107(27.5)NS
Chemotherapy [n(%)]
        Yes19(30.2)1(4.8)9(42.9)9(42.9)0.004
        No44(69.8)20(95.2)12(57.1)12(57.1)
Dindo-Claviene
        050(79.4)16(76.2)18(85.7)16(76.2)
        II IIIa3(4.8) 1(1.6)1(4.8) 0(0)1(4.8) 0(0)1(4.8) 1(4.8)NS
        IIIb2(3.2)0(0)1(4.8)1(4.8)
        V7(11.1)4(19)1(4.8)2(9.5)
TNM T stage [n(%)]
        15(7.9)0(0)2(9.5)3(14.3)
        21(1.6)0(0)0(0)1(4.8)
        336(57.1)17(81)8(38.1)11(52.4)NS
        4a8(12.7)2(9.5)3(14.3)3(14.3)
        4b13(20.6)2(9.5)8(38.1)3(14.3)
TNM N stage [n(%)]
        06(11.1)0(0)3(14.3)3(15)
        1 25(9.3)3(23.1)2(9.5)0(0)NS
        215(27.8)3(23.1)8(38.1)4(20)
        3a9(16.7)1(7.7)3(14.3)5(25)
        3b19(35.2)6(46.2)5(23.8)8(40)
UICC stage [n(%)]
        IIIa2(3.2)0(0)1(4.8)1(4.8)
        IIIc4(6.3)0(0)2(9.5)2(9.5)NS
        IV57(90.5)21(100)18(85.7)18(85.7)
Positive LNs [n(IQR)]7(17.7)11(23)5.5(18.7)12.5(12.2)
All LNs [n±SD]28.2±11.518±927.6±14.626±170.028
Grade [n(%)]
        Well Moderate6(12.5)2(16.7)2(10)2(12.5)NS
        Moderate13(27.1)4(33.3)5(25)4(25)NS
        Poor29(60.4)6(50)13(65)10(62.5)
Type [n(%)] of gastrectomy
        Subtotal22(34.9)12(57.1)6(28.6)4(19)
        Total34(54)8(38.1)14(66.7)12(57.1)
        Total with distal esophagectomy4(3.2)0(0)0(0)4(19)NS
        Distal esophagectomy & proximal2(1.6)1(4.8)1(4.8)0(0)
        gastrectomy Stump resection1(1.6)0(0)0(0)1(4.8)
Location [n(%)]
        Stump1(1.6)0(0)0(0)1(4.8)
        Entire6(9.5)2(9.5)9(42.9)3(14.3)
        Proximal10(15.9)2(9.5)9(42.9)6(28.6)0.045
        Middle20(31.7)6(28.6)2(9.5)5(23.8)
        Distal26(41.3)11(52.4)1(4.8)6(28.6)
ASA score [n(%)]
        I16(25.4)6(28.6)6(28.6)4(19)NS
        II32(50.8)9(42.9)12(57.1)11(52.4)
        III15(23.8)6(28.6)3(14.3)6(28.6)
Lymphadenectomy [n(%)]
        D126(41.3)17(81)5(23.8)4(19)< 0.0001
        D237(58.7)4(19)16(76.2)17(81)
R0 [n(%)]39(61.9)0(0)18(85.7)21(100)< 0.0001
Number metastases of liver [n(%)]
        123(54.8)4(19)19(90.5)0(0)< 0.0001
        2–34(9.5)2(9.5)2(9.5)0(0)
        > 315(35.7)15(71.4)0(0)0(0)
Grade [n(%)]
        Well6(9.5)2(16.7)2(10)2(12.5)
        Moderate13(27.1)4(33.3)5(25)4(25)NS
        Poor29(60.4)6(50)13(65)10(62.5)
Hospital stay [n(IQR)]13(8.5)12(6.5)13.5(8)14(12.7)NS

Characteristics of liver metastases and recurrence sites in the group of patients with synchronous liver metastases and gastric resection with curative intent (LMR)

Case No.Involved segmentNumber of metastasesType of resectionRecurrence site
1II1Segmentectomy0
2IV1Metastasectomy0
3III1Segmentectomycarcinomatosis Peritoneal
4II/III1SegmentectomyLiver metastases
5III1Metastasectomy0
6VII1Metastasectomy0
7III1Metastasectomyrecurrence Local
8III1Segmentectomycarcinomatosis Peritoneal
9VIII1MetastasectomyLiver metastases
10III1Segmentectomy0
11V1Metastasectomyrecurrence Local
12IV, II3MetastasectomyLiver metastases
13II/III1MetastasectomyLiver metastases
14III1Metastasectomy0
15II/III1secienectomy Left lateral0
16III1Metastasectomy0
17III1Metastasectomycarcinomatosis Peritoneal
18V, VIII2MetastasectomyLiver metastases
19VII1Radio frequency ablationLiver and metastases peritoneal carcinomatosis
20VII1Radio ablation frequency0
21III1Segmentectomy0

Cox proportional hazard model for survival after gastric cancer resection with liver metastases

HR95% CIp
LowerUpper
Age1.4971.2131.846<0.0001
Gender55.2374.626659.5940.002
ASA score0.0490.0090.261<0.0001
Ca 19-9111.0010.02
Hb0.9180.8640.9740.005
Additional liver resection0.00100.029<0.0001
Tumour grade8.2761.97134.7530.004
UICC stage000.0030.002
TNM N stage0.3860.1630.9170.031
eISSN:
1581-3207
Idioma:
Inglés
Calendario de la edición:
4 veces al año
Temas de la revista:
Medicine, Clinical Medicine, Internal Medicine, Haematology, Oncology, Radiology